Based on the Collplant Biotechnologies Ltd stock forecast from 1 analysts, the average analyst target price for Collplant Biotechnologies Ltd is USD 11.00 over the next 12 months. Collplant Biotechnologies Ltd’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Collplant Biotechnologies Ltd is Very Bearish, which is based on 0 positive signals and 8 negative signals. At the last closing, Collplant Biotechnologies Ltd’s stock price was USD 2.46. Collplant Biotechnologies Ltd’s stock price has changed by +1.87% over the past week, -24.88% over the past month and -52.56% over the last year.
No recent analyst target price found for Collplant Biotechnologies Ltd
No recent average analyst rating found for Collplant Biotechnologies Ltd
Company Overview Collplant Biotechnologies Ltd
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was incorporated in 1981 and is headquartered in Rehovot, Israel. Read Less
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type...Read More
Frequently Asked Questions About Collplant Biotechnologies Ltd (CLGN) Stock
Based on ratings from 1 analysts Collplant Biotechnologies Ltd's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on CLGN's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for CLGN is USD 11.00 over the next 12 months. The maximum analyst target price is USD 11 while the minimum anlayst target price is USD 11.
CLGN stock's Price/Earning ratio is 475.50.
Our analysis grades CLGN stock's Price / Earning ratio at F. This means that CLGN stock's Price/Earning ratio is above 98% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this CLGN may be a overvalued for its sector.
The last closing price of CLGN's stock was USD 2.46.
The most recent market capitalization for CLGN is USD 0.03B.
Based on targets from 1 analysts, the average taret price for CLGN is projected at USD 11.00 over the next 12 months.
This means that CLGN's stock price may go up by +348.07% over the next 12 months.
We can't find any ETFs which contains Collplant Biotechnologies Ltd's stock.
As per our most recent records Collplant Biotechnologies Ltd has 57 Employees.
Collplant Biotechnologies Ltd's registered address is Weizmann Science Park, Rehovot, Israel, 7670104.
You can get more information about it from Collplant Biotechnologies Ltd's website at https://www.collplant.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Frequently Asked Questions About Collplant Biotechnologies Ltd (CLGN) Stock
Based on ratings from 1 analysts Collplant Biotechnologies Ltd's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on CLGN's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for CLGN is USD 11.00 over the next 12 months. The maximum analyst target price is USD 11 while the minimum anlayst target price is USD 11.
CLGN stock's Price/Earning ratio is 475.50.
Our analysis grades CLGN stock's Price / Earning ratio at F. This means that CLGN stock's Price/Earning ratio is above 98% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this CLGN may be a overvalued for its sector.
The last closing price of CLGN's stock was USD 2.46.
The most recent market capitalization for CLGN is USD 0.03B.
Based on targets from 1 analysts, the average taret price for CLGN is projected at USD 11.00 over the next 12 months.
This means that CLGN's stock price may go up by +348.07% over the next 12 months.
We can't find any ETFs which contains Collplant Biotechnologies Ltd's stock.
As per our most recent records Collplant Biotechnologies Ltd has 57 Employees.
Collplant Biotechnologies Ltd's registered address is Weizmann Science Park, Rehovot, Israel, 7670104.
You can get more information about it from Collplant Biotechnologies Ltd's website at https://www.collplant.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for CLGN !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
